{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:58:16Z","timestamp":1783479496178,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.rvsc.2017.12.010","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T12:56:24Z","timestamp":1513601784000},"page":"187-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacodynamic interactions of amikacin with selected \u03b2-lactams and fluoroquinolones against canine Escherichia coli isolates"],"prefix":"10.1016","volume":"117","author":[{"given":"Georgios A.","family":"Delis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria I.","family":"Siarkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida I.","family":"Vingopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koutsoviti-Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios C.","family":"Batzias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rvsc.2017.12.010_bb0005","first-page":"5465678","article-title":"Application of PK\/PD modeling in veterinary field: dose optimization and drug resistance prediction","author":"Ahmad","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.rvsc.2017.12.010_bb0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.rvsc.2017.12.010_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/18.1.51","article-title":"Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model","volume":"18","author":"Bamberger","year":"1986","journal-title":"J. Antimicrob. Chemother."},{"issue":"1\u20132","key":"10.1016\/j.rvsc.2017.12.010_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/avj.12279","article-title":"In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine","volume":"93","author":"Bennie","year":"2015","journal-title":"Aust. Vet. J."},{"issue":"1","key":"10.1016\/j.rvsc.2017.12.010_bb0025","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/AAC.04011-14","article-title":"Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosain a model of infected THP-1 monocytes","volume":"59","author":"Buyck","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.rvsc.2017.12.010_bb0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1128\/AAC.40.3.677","article-title":"Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa","volume":"40","author":"Cappelletty","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.rvsc.2017.12.010_bb0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11095-006-9783-x","article-title":"Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosain a systemic rat infection model","volume":"23","author":"Chan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.rvsc.2017.12.010_bb0040","series-title":"CLSI Document VET01-A4","article-title":"Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2013"},{"key":"10.1016\/j.rvsc.2017.12.010_bb0045","series-title":"CLSI Document VET01-S","article-title":"Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.rvsc.2017.12.010_bb0050","series-title":"CLSI Document M100","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017"},{"issue":"5","key":"10.1016\/j.rvsc.2017.12.010_bb0055","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jac\/dkg238","article-title":"In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms","volume":"51","author":"Dawis","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.rvsc.2017.12.010_bb0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.rvsc.2010.03.018","article-title":"Pharmacodynamics of amoxicillin against Mannheimia haemolytica and Pasteurella multocidaand pharmacokinetic\/pharmacodynamic (PK\/PD) correlation in sheep","volume":"89","author":"Delis","year":"2010","journal-title":"Res. Vet. Sci."},{"issue":"12","key":"10.1016\/j.rvsc.2017.12.010_bb0065","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1128\/AAC.45.12.3328-3333.2001","article-title":"Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae","volume":"45","author":"Desbiolles","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.rvsc.2017.12.010_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1179\/joc.2005.17.1.46","article-title":"In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or \u03b2-lactams against extended spectrum \u03b2-lactamase-producing Escherichia coli","volume":"17","author":"Drago","year":"2005","journal-title":"J. Chemother."},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0075","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0924-8579(00)00317-4","article-title":"Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents","volume":"17","author":"Gradelski","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.rvsc.2017.12.010_bb0080","series-title":"Infectious Diseases of the Dog and Cat","author":"Greene","year":"2012"},{"issue":"5","key":"10.1016\/j.rvsc.2017.12.010_bb0085","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1128\/AAC.28.5.663","article-title":"Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"28","author":"Haller","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0090","first-page":"106","article-title":"Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill","volume":"57","author":"Hosgor-Limoncu","year":"2008","journal-title":"West Indian Med. J."},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2885.2008.00938.x","article-title":"Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs","volume":"31","author":"KuKanich","year":"2008","journal-title":"J. Vet. Pharmacol. Therap."},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jvim.14627","article-title":"Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases","volume":"31","author":"Lappin","year":"2017","journal-title":"J. Vet. Intern. Med."},{"issue":"3","key":"10.1016\/j.rvsc.2017.12.010_bb0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/AAC.37.3.523","article-title":"The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlineal pharmacodynamic interactions","volume":"37","author":"Li","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.rvsc.2017.12.010_bb0110","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1939-1676.2011.00821.x","article-title":"Enteropathogenic bacteria in dogs and cats: diagnosis, epidemiology, treatment, and control","volume":"25","author":"Marks","year":"2011","journal-title":"J. Vet. Intern. Med."},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2885.2009.01104.x","article-title":"Pharmacokinetics of ceftazidime after intravenous, intramuscular and subcutaneous administration to dogs","volume":"33","author":"Monfrinotti","year":"2010","journal-title":"J. Vet. Pharmacol. Therap."},{"key":"10.1016\/j.rvsc.2017.12.010_bb0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2016.05.020","article-title":"Antimicrobial susceptibility monitoring of bacterial pathogens isolated from respiratory tract infections in dogs and cats across Europe: ComPath results","volume":"191","author":"Morrissey","year":"2016","journal-title":"Vet. Microbiol."},{"issue":"4","key":"10.1016\/j.rvsc.2017.12.010_bb0125","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/AAC.01146-08","article-title":"Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.rvsc.2017.12.010_bb0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-3164.2011.01030.x","article-title":"Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?","volume":"23","author":"Papich","year":"2012","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.rvsc.2017.12.010_bb0135","series-title":"Veterinary Pharmacology and Therapeutics","first-page":"915","article-title":"Aminoglycoside antibiotics","author":"Papich","year":"2009"},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0140","first-page":"DC13","article-title":"In vitro fractional inhibitory concentration (FIC) study of cefixime and azithromycin fixed dose combination (FDC) against respiratory clinical isolates","volume":"9","author":"Patil","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"issue":"6","key":"10.1016\/j.rvsc.2017.12.010_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2885.2011.01293.x","article-title":"Lack of interaction of metoclopramide on oral amoxicillin kinetics in dogs","volume":"34","author":"Rebuelto","year":"2011","journal-title":"J. Vet. Pharmacol. Therap."},{"issue":"1","key":"10.1016\/j.rvsc.2017.12.010_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4066\/AMJ.2015.2096","article-title":"Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa","volume":"8","author":"Rizvi","year":"2015","journal-title":"Australas Med J"},{"key":"10.1016\/j.rvsc.2017.12.010_bb0160","doi-asserted-by":"crossref","first-page":"408205","DOI":"10.1155\/2015\/408205","article-title":"Multidrug resistance in Escherichia coli strains isolated from infections in dogs and cats in Poland (2007\u20132013)","volume":"2015","author":"Rzewuska","year":"2015","journal-title":"ScientificWorldJournal"},{"issue":"2","key":"10.1016\/j.rvsc.2017.12.010_bb0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-014-2231-7","article-title":"Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin","volume":"34","author":"Safarika","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"10","key":"10.1016\/j.rvsc.2017.12.010_bb0170","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1128\/AAC.47.10.3296-3304.2003","article-title":"Inhibition of aminoglycoside 6\u2032-N-Acetytransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides","volume":"47","author":"Sarno","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.rvsc.2017.12.010_bb0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1040638715586439","article-title":"Long-term survival in a dog with meningoencephalitis and epidural abscessation due to Actinomycesspecies","volume":"27","author":"Song","year":"2015","journal-title":"J. Vet. Diagn. Invest."},{"issue":"6","key":"10.1016\/j.rvsc.2017.12.010_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126479","article-title":"Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumoniae isolates","volume":"10","author":"Stein","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.rvsc.2017.12.010_bb0185","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1128\/AAC.48.11.4315-4321.2004","article-title":"Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents","volume":"48","author":"Tam","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rvsc.2017.12.010_bb0190","series-title":"Antimicrobial Agents: Antibacterials and Antifungals","first-page":"453","article-title":"Aminocyclitol aminoglycosides","author":"Veyssier","year":"2005"},{"issue":"6","key":"10.1016\/j.rvsc.2017.12.010_bb0195","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1128\/AAC.01452-08","article-title":"In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including \u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.rvsc.2017.12.010_bb0200","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/jac\/dku090","article-title":"Emergence and maintenance of multidrug-resistant Escherichia coli of canine origin harbouring a blaCMY-2-IncI1\/ST65 plasmid and topoisomerase mutations","volume":"69","author":"Vingopoulou","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rvsc.2017.12.010_bb0205","doi-asserted-by":"crossref","first-page":"263768","DOI":"10.4061\/2011\/263768","article-title":"Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases","volume":"2011","author":"Weese","year":"2011","journal-title":"Vet. Med. Int."},{"issue":"8","key":"10.1016\/j.rvsc.2017.12.010_bb0210","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","article-title":"Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test","volume":"40","author":"White","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.rvsc.2017.12.010_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijos.2014.65","article-title":"Strategies for combating bacterial biofilm infections","volume":"7","author":"Wu","year":"2015","journal-title":"Int. J. Oral Sci."}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528817309517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528817309517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:09:26Z","timestamp":1758514166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034528817309517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":42,"alternative-id":["S0034528817309517"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2017.12.010","relation":{},"ISSN":["0034-5288"],"issn-type":[{"value":"0034-5288","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic interactions of amikacin with selected \u03b2-lactams and fluoroquinolones against canine Escherichia coli isolates","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}